Summary

for people ages 40 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

The purpose of this study is to assess the long-term safety and efficacy of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).

Keywords

Progressive Supranuclear Palsy (PSP) tauopathy Steele-Richardson-Olszewski Syndrome PSP Supranuclear Palsy, Progressive ABBV-8E12

Eligibility

You can join if…

Open to people ages 40 years and up

  • Subject completed the 52-week treatment period in Study M15-562 (NCT02985879).
  • In the opinion of the investigator, the subject was compliant during participation in Study M15-562 (NCT02985879).
  • Subject has an identified, reliable, study partner (e.g., caregiver, family member,social worker, or friend).

You CAN'T join if...

  • Subjects who weigh less than 44 kg (97 lbs) at the time of study entry.
  • Any contraindication or inability to tolerate brain magnetic resonance imaging (MRI).
  • Subject has any significant change in his/her medical condition that could interfere with the subject's participation in the study, could place the subject at increased risk, or could confound interpretation of study results.
  • More than 8 weeks have elapsed since the subject received his/her last dose of study drug in Study M15-562 (NCT02985879).
  • Subject is considered by the investigator, for any reason, to be an unsuitable candidate to receive ABBV-8E12 or the subject is considered by the investigator to be unable or unlikely to comply with the dosing schedule or study evaluations.

Locations

  • Univ California, San Francisco /ID# 165553 accepting new patients
    San Francisco California 94143-2204 United States
  • University of California, Los Angeles /ID# 165669 accepting new patients
    Los Angeles California 90095 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
ID
NCT03391765
Phase
Phase 2
Study Type
Interventional
Last Updated